MiRXES, Hengrui Pharmaceuticals soar on Hong Kong debut

About this update from Mirxes Holding Company Limited

** MiRXES Holding HKEX:2629 climbs to HK$31.95 on HK debut, up 37.1% from offer price of HK$23.30** Stock last up 31.8%, outpacing Hang Seng Index's HSI:HSI 0.5% gain and Hang Seng Biotech index's HSI:HSHKBIO 2.3% jump** Singapore-headquartered micro ribonucleic acid (miRNA) tech co, which specialises in early cancer detection and precision medicine, sells 46.6 mln shares in global offering, raising HK$1.09 bln ($139.2 mln) for R&D, manufacturing, commercialisation of core product** Jiangsu Hengrui Pharmaceuticals SSE:600276 jumps to HK$60.5 on HK debut, up 37.3% from offer price of HK$44.05** Chinese oncology drug developer sells 224.52 mln H-shares, raising HK$9.89 bln ($1.26 bln) for R&D, constructing production facilities** Hengrui's Shanghai stock SSE:600276 slips 1.6%($1 = KH$7.8302)

View stock analysis, news, and events for Mirxes Holding Company Limited